Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.
about
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysisBisphosphonates and other bone agents for breast cancerCirculating tumor cells in breast cancerAdjuvant bisphosphonates in patients with breast cancer: does the potency matter?Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidenceBone-Targeted TherapyBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaUpdate 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant RadiotherapyPotential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastasesInfluence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Oral bisphosphonate use and breast cancer incidence in postmenopausal women.Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.ASCO 2009: What's New in Breast Cancer Therapy?The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Breast Cancer 2012 - New AspectsAntitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.Prevention of bone metastases and management of bone health in early breast cancer.NCCN Task Force Report: Bone Health in Cancer Care.Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cellsOptimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary gameTreatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticePrevention of Bone Metastases in Breast Cancer Patients. Therapeutic PerspectivesCan Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian GuidelinePrevention and Treatment of Bone Metastases in Breast CancerA meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma.The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany.Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes.Importance of antiresorptive therapies for patients with bone metastases from solid tumors.Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts.Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort.Does estrogen play a role in response to adjuvant bone-targeted therapies?Mitochondrial permeability transition pore as a selective target for anti-cancer therapyDifferent prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
P2860
Q21132670-836C14C9-45E0-4FB7-93CD-0EE5B7B8F280Q24203656-9313E818-7852-4BB3-9CB0-E0B3F164F821Q26774808-B6837E57-7711-4354-A2AC-989817C74AD5Q26781435-F7D07239-E03D-48D5-B2FA-47411C9CC1E5Q26795493-7D668D81-5662-4965-B30A-AAE476BDA660Q28081294-F37A5F9F-0F53-4FED-AB26-6EBDDE4E9134Q28081996-36D55F6E-0AAC-4811-A8BA-A769483FEDCDQ30318610-43F29E19-DF7B-4DB0-9D6E-33ABA5CEC89CQ33447971-3C38200D-DEA0-44BF-B121-E5972372BADBQ33587199-CCDE7EFE-BEBF-4F48-B5BD-D8430BB518BBQ34042715-0E3E541D-57C5-471F-AE11-4408E3E10241Q34049239-B1264184-105A-434E-BC8D-1A5D9990464AQ34122791-94F2B3D7-0408-4D5D-85BD-7E096D7D422CQ34127953-E2FE94B0-6C97-4B09-A0E1-98402432D7EEQ34138399-BFCF5F36-5925-4183-8DEF-9353CC5751F0Q34145863-31B043C6-B34F-4EDB-8AEA-CF66239CD1EDQ34209663-545FEC7F-581B-433A-8126-1688DF40B816Q34348233-C79968D1-19B9-4FF7-B78A-8C091ED38B3EQ34613485-C2C6EA84-327C-49B4-A638-E9B10272A426Q34617936-FDD9AADA-2C25-4B11-9B41-4581AFC88FA8Q34896573-FF0A22E6-A985-4A82-8C74-EEC1D1D4722AQ34939979-FED90379-D311-48C5-A863-B40042271BC6Q34967135-B9E0513D-D073-4632-A74D-D3B4620C4640Q35583788-07C9A6FF-F4CC-42A9-9FBD-4D27BB31753CQ35653826-4F2ED814-E678-44B2-AACD-62C7DC4E01C1Q35667196-C68A8685-1DB0-4774-A465-316DBD805E47Q35667318-6425B425-779F-410A-A30B-B991177F7814Q35750453-E1E5A02E-10E9-4123-8A02-0A4340D67EC7Q35750472-B5F25E5E-5CEE-4ECE-ABAA-20EC56B73A7DQ35750652-C9A93FA3-6269-4EB4-8A9C-CC6BD11F2BC2Q35870578-81A10DE3-FEAD-4A18-B375-D2B22CAF9AB8Q36187063-D151E70B-902C-4D0E-87B8-C7BE1CCE1617Q36216730-D8C9F7AD-A4AE-43EA-819E-BEAE1A7B8958Q36283738-6595A98A-984A-495D-8ABC-E0A8FD85619AQ36491357-3267FBE2-D866-4CE9-91BF-77638C7C813BQ36491378-66E6038E-8343-40C6-AF42-38776DA5AF9AQ36491459-942EF3A5-F221-4533-A732-A6447EEACF9AQ36491529-26C2B1F0-1F37-47A5-8F46-0D194B13F637Q36668047-A232414D-50EE-4FEB-9D06-1350CC00773EQ36925557-44BC6808-E111-4242-B75C-22195521E1F2
P2860
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant oral clodronate impro ...... marrow: a long-term follow-up.
@en
Adjuvant oral clodronate impro ...... marrow: a long-term follow-up.
@nl
type
label
Adjuvant oral clodronate impro ...... marrow: a long-term follow-up.
@en
Adjuvant oral clodronate impro ...... marrow: a long-term follow-up.
@nl
prefLabel
Adjuvant oral clodronate impro ...... marrow: a long-term follow-up.
@en
Adjuvant oral clodronate impro ...... marrow: a long-term follow-up.
@nl
P2093
P2860
P356
P1433
P1476
Adjuvant oral clodronate impro ...... marrow: a long-term follow-up.
@en
P2093
E F Solomayer
P2860
P304
P356
10.1093/ANNONC/MDN429
P577
2008-07-29T00:00:00Z